Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice.
Guardado en:
Autores principales: | Zuqiang Liu, Yan Ge, Haiyan Wang, Congrong Ma, Mathilde Feist, Songguang Ju, Z. Sheng Guo, David L. Bartlett |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf8c62b2e7b9492694731295e94b4d6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Zuqiang Liu, et al.
Publicado: (2017) -
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Yi Wang, et al.
Publicado: (2021) -
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
por: Julie Delaloye, et al.
Publicado: (2009) -
The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
por: Franziska Tanneberger, et al.
Publicado: (2021) -
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Arwen F. Altenburg, et al.
Publicado: (2017)